A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus is a PHASE1 clinical asset sponsored by Lyell Immunopharma, Inc. in Systemic Lupus Erythematosus, Lupus Nephritis. SEO and diligence focus: IMPT-514, IMPT-514, IMPT-514, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.